Overview

TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer

Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm study evaluating the safety and tolerability of TEW-7197 in combination with paclitaxel in metastatic gastric cancer patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
MedPacto, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel